Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells

Stefan Rupp, Cornel Badorff, Masamichi Koyanagi, Carmen Urbich, Stephan Fichtlscherer, Alexandra Aicher, Andreas M. Zeiher, Stefanie Dimmeler

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Human endothelial progenitor cells (EPCs) can differentiate into cardiomyogenic cells in vitro. We tested the effects of statin therapy on the differentiation rate of EPCs from patients with coronary artery disease (CAD), who may benefit from autologous cell therapy. EPCs from 3 age-matched groups were tested: No CAD (n = 13), CAD patients with (n = 10) or without (n = 16) statin therapy. From 4 CAD patients, EPCs were tested before and after 4 weeks of therapy with 20 mg atorvastatin. After 6 days of co-culture with rat neonatal cardiomyocytes, EPC differentiation was quantified by immunostaining for α-sarcomeric actinin flow cytometry analysis. After 6 days of co-culture, the percentage of α-sarcomeric actinin-positive EPCs was significantly (p = 0.014) higher in EPCs from adults without CAD (8.07% ± 1.48% of EPCs) compared to EPCs from CAD patients without statin (3.56% ± 0.72%). Importantly, patients with statin therapy revealed significantly higher numbers of α-sarcomeric actinin-positive EPCs (6.36% ± 0.69%, p = 0.01) compared to CAD patients without statin. In addition, statin therapy resulted in a significant (p = 0.017) increase of EPC differentiation in all 4 CAD patients investigated before and 4 weeks after statin therapy. The survival of EPCs did not differ between the different groups suggesting that the regulation of EPC differentiation is not secondary to altered EPC survival. In vitro, EPC treatment with 0.1 μM atorvastatin did not affect EPC differentiation (116.15% ± 49.11 % of control). EPCs from patients with CAD display impaired differentiation into cardiomyogenic cells. This defect can be improved by in vivo, statin therapy.

Original languageEnglish
Pages (from-to)61-68
Number of pages8
JournalBasic Research in Cardiology
Volume99
Issue number1
DOIs
Publication statusPublished - Jan 1 2004

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coronary Artery Disease
Cell Differentiation
Therapeutics
Actinin
Endothelial Progenitor Cells
Coculture Techniques

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells. / Rupp, Stefan; Badorff, Cornel; Koyanagi, Masamichi; Urbich, Carmen; Fichtlscherer, Stephan; Aicher, Alexandra; Zeiher, Andreas M.; Dimmeler, Stefanie.

In: Basic Research in Cardiology, Vol. 99, No. 1, 01.01.2004, p. 61-68.

Research output: Contribution to journalArticle

Rupp, Stefan ; Badorff, Cornel ; Koyanagi, Masamichi ; Urbich, Carmen ; Fichtlscherer, Stephan ; Aicher, Alexandra ; Zeiher, Andreas M. ; Dimmeler, Stefanie. / Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells. In: Basic Research in Cardiology. 2004 ; Vol. 99, No. 1. pp. 61-68.
@article{db8eb4f3ecb744578d0f436aa4905dfd,
title = "Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells",
abstract = "Human endothelial progenitor cells (EPCs) can differentiate into cardiomyogenic cells in vitro. We tested the effects of statin therapy on the differentiation rate of EPCs from patients with coronary artery disease (CAD), who may benefit from autologous cell therapy. EPCs from 3 age-matched groups were tested: No CAD (n = 13), CAD patients with (n = 10) or without (n = 16) statin therapy. From 4 CAD patients, EPCs were tested before and after 4 weeks of therapy with 20 mg atorvastatin. After 6 days of co-culture with rat neonatal cardiomyocytes, EPC differentiation was quantified by immunostaining for α-sarcomeric actinin flow cytometry analysis. After 6 days of co-culture, the percentage of α-sarcomeric actinin-positive EPCs was significantly (p = 0.014) higher in EPCs from adults without CAD (8.07{\%} ± 1.48{\%} of EPCs) compared to EPCs from CAD patients without statin (3.56{\%} ± 0.72{\%}). Importantly, patients with statin therapy revealed significantly higher numbers of α-sarcomeric actinin-positive EPCs (6.36{\%} ± 0.69{\%}, p = 0.01) compared to CAD patients without statin. In addition, statin therapy resulted in a significant (p = 0.017) increase of EPC differentiation in all 4 CAD patients investigated before and 4 weeks after statin therapy. The survival of EPCs did not differ between the different groups suggesting that the regulation of EPC differentiation is not secondary to altered EPC survival. In vitro, EPC treatment with 0.1 μM atorvastatin did not affect EPC differentiation (116.15{\%} ± 49.11 {\%} of control). EPCs from patients with CAD display impaired differentiation into cardiomyogenic cells. This defect can be improved by in vivo, statin therapy.",
author = "Stefan Rupp and Cornel Badorff and Masamichi Koyanagi and Carmen Urbich and Stephan Fichtlscherer and Alexandra Aicher and Zeiher, {Andreas M.} and Stefanie Dimmeler",
year = "2004",
month = "1",
day = "1",
doi = "10.1007/s00395-003-0441-3",
language = "English",
volume = "99",
pages = "61--68",
journal = "Basic Research in Cardiology",
issn = "0300-8428",
publisher = "D. Steinkopff-Verlag",
number = "1",

}

TY - JOUR

T1 - Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells

AU - Rupp, Stefan

AU - Badorff, Cornel

AU - Koyanagi, Masamichi

AU - Urbich, Carmen

AU - Fichtlscherer, Stephan

AU - Aicher, Alexandra

AU - Zeiher, Andreas M.

AU - Dimmeler, Stefanie

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Human endothelial progenitor cells (EPCs) can differentiate into cardiomyogenic cells in vitro. We tested the effects of statin therapy on the differentiation rate of EPCs from patients with coronary artery disease (CAD), who may benefit from autologous cell therapy. EPCs from 3 age-matched groups were tested: No CAD (n = 13), CAD patients with (n = 10) or without (n = 16) statin therapy. From 4 CAD patients, EPCs were tested before and after 4 weeks of therapy with 20 mg atorvastatin. After 6 days of co-culture with rat neonatal cardiomyocytes, EPC differentiation was quantified by immunostaining for α-sarcomeric actinin flow cytometry analysis. After 6 days of co-culture, the percentage of α-sarcomeric actinin-positive EPCs was significantly (p = 0.014) higher in EPCs from adults without CAD (8.07% ± 1.48% of EPCs) compared to EPCs from CAD patients without statin (3.56% ± 0.72%). Importantly, patients with statin therapy revealed significantly higher numbers of α-sarcomeric actinin-positive EPCs (6.36% ± 0.69%, p = 0.01) compared to CAD patients without statin. In addition, statin therapy resulted in a significant (p = 0.017) increase of EPC differentiation in all 4 CAD patients investigated before and 4 weeks after statin therapy. The survival of EPCs did not differ between the different groups suggesting that the regulation of EPC differentiation is not secondary to altered EPC survival. In vitro, EPC treatment with 0.1 μM atorvastatin did not affect EPC differentiation (116.15% ± 49.11 % of control). EPCs from patients with CAD display impaired differentiation into cardiomyogenic cells. This defect can be improved by in vivo, statin therapy.

AB - Human endothelial progenitor cells (EPCs) can differentiate into cardiomyogenic cells in vitro. We tested the effects of statin therapy on the differentiation rate of EPCs from patients with coronary artery disease (CAD), who may benefit from autologous cell therapy. EPCs from 3 age-matched groups were tested: No CAD (n = 13), CAD patients with (n = 10) or without (n = 16) statin therapy. From 4 CAD patients, EPCs were tested before and after 4 weeks of therapy with 20 mg atorvastatin. After 6 days of co-culture with rat neonatal cardiomyocytes, EPC differentiation was quantified by immunostaining for α-sarcomeric actinin flow cytometry analysis. After 6 days of co-culture, the percentage of α-sarcomeric actinin-positive EPCs was significantly (p = 0.014) higher in EPCs from adults without CAD (8.07% ± 1.48% of EPCs) compared to EPCs from CAD patients without statin (3.56% ± 0.72%). Importantly, patients with statin therapy revealed significantly higher numbers of α-sarcomeric actinin-positive EPCs (6.36% ± 0.69%, p = 0.01) compared to CAD patients without statin. In addition, statin therapy resulted in a significant (p = 0.017) increase of EPC differentiation in all 4 CAD patients investigated before and 4 weeks after statin therapy. The survival of EPCs did not differ between the different groups suggesting that the regulation of EPC differentiation is not secondary to altered EPC survival. In vitro, EPC treatment with 0.1 μM atorvastatin did not affect EPC differentiation (116.15% ± 49.11 % of control). EPCs from patients with CAD display impaired differentiation into cardiomyogenic cells. This defect can be improved by in vivo, statin therapy.

UR - http://www.scopus.com/inward/record.url?scp=0347629192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347629192&partnerID=8YFLogxK

U2 - 10.1007/s00395-003-0441-3

DO - 10.1007/s00395-003-0441-3

M3 - Article

VL - 99

SP - 61

EP - 68

JO - Basic Research in Cardiology

JF - Basic Research in Cardiology

SN - 0300-8428

IS - 1

ER -